Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed AL Amyloidosis
NCT03236792Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jun 2017
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib in amyloid light chain amyloidosis, sponsored by Icahn School of Medicine at Mount Sinai. Started Jun 2017; status: completed.
02
Drugs
ixazomib
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT03236792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03236792.